**Impact of Pretreatment Hydronephrosis on the Success Rate of Shock Wave Lithotripsy in Patients with Ureteral Stone**

Ki Don Chang¹, Joo Yong Lee¹, Sung Yoon Park², Dong Hyuk Kang¹, Hyung Ho Lee¹, and Kang Su Cho³

¹Department of Urology and Urological Science Institute, Severance Hospital, Yonsei University College of Medicine, Seoul; ²Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul; ³Department of Urology and Urological Science Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

**Purpose:** To evaluate predictors of the success rate for one session of shock wave lithotripsy (SWL), focusing on the relationships between pretreatment hydronephrosis grade and one-session SWL success rates.

**Materials and Methods:** The medical records of 1824 consecutive patients who underwent an initial session of SWL for treatment of urinary stones between 2005 and 2013 were reviewed. After exclusion, 700 patients with a single, 4–20 mm diameter radiopaque calculus were included in the study.

**Results:** The mean maximal stone length (MSL) and skin-to-stone distance were 9.2±3.9 and 110.8±18.9 mm, respectively. The average values for mean stone density (MSD) and stone heterogeneity index (SHI) were 707.0±272.1 and 244.9±110.1, respectively. One-session success rates were 68.4, 75.0, 75.1, 54.0, and 10.5% in patients with hydronephrosis grade 0, 1, 2, 3, and 4, respectively. Patients were classified into success or failure groups based on SWL outcome. Multivariate logistic regression analyses revealed that MSL (odds ratio (OR) 0.888, 95% confidence intervals (CI): 0.841–0.934, p<0.001), MSD (OR 0.996, 95% CI: 0.995–0.997, p<0.001), SHI (OR 1.007, 95% CI: 1.005–1.010, p<0.001), and pretreatment hydronephrosis grade (OR 0.601, 95% CI: 0.368–0.988, p=0.043) were significantly associated with one-session success.

**Conclusion:** Pretreatment grades 3 or 4 hydronephrosis were associated with failure of SWL in patients with a single ureteral stone. In the presence of severe hydronephrosis, especially hydronephrosis grade 4; physicians should proceed cautiously in choosing and offering SWL as the primary treatment for ureteral stone.

**Key Words:** Ureteral calculi, high-energy shock waves, lithotripsy, hydronephrosis

---

**INTRODUCTION**

Ureteral stone is one of the most common urologic diseases. Affected patients can experience extreme pain. There are many options for ureteral stone treatment [e.g., shock wave lithotripsy (SWL), and ureteroscopic, laparoscopic, or open surgery]. Since the 1980s, SWL has been recommended as a non-invasive, effective, first-line treatment for small-sized radio-opaque stones (<2 cm diameter).¹ The overall stone-free rate after treatment using SWL is 80–90%.²³ A patient’s age, sex, and stone characteristics (stone site, size, and density) are factors associated with stone-free rates. The number of stones, a history of urolithiasis, presence of renal colic, degree of hydronephrosis, and presence of a double J stent are additional factors associated with stone-free rates after treatment using SWL.⁴⁵

Ureteral stone is the most common cause of ipsilateral hydronephrosis. The presence of one or more ureteral stones warrants urgent intervention to resolve the patient’s symptoms and to prevent damage to renal function. The relationship between the degree of preoperative hydronephrosis and stone free rate...
after SWL has been studied. However, unanswered questions remain, and a complete understanding would aid clinical decision-making during treatment selection.5,6 We aimed to investigate the predictors of one-session success rates after treatment using SWL; we specifically focused on the significance of pretreatment hydronephrosis in patients with a ureteral stone.

MATERIALS AND METHODS

Patient cohort
Medical records were obtained from a database of patients (n=1824) who underwent an initial session of SWL between November 2005 and December 2014 at Severance Hospital, Seoul, Korea. The study inclusion criteria were a single, 4–20 mm, radiopaque calculus located within the ureter on plain-film X-rays, presentation within 1 month prior to SWL treatment, and no evidence of stone migration. Patients with bilateral ureteral stones, urinary tract congenital anomalies, single kidney, concomitant medical expulsive treatment, or a history of stone surgery were excluded from the analysis. Data from a total of 700 patients were eligible for the analysis.

Good clinical practice protocols
The study was performed in accordance with all applicable laws and regulations, good clinical practices, and the ethical principles described in the Declaration of Helsinki. The Institutional Review Board of Severance Hospital approved the study protocol (4-2016-0791). The study was exempt from the need for written informed consent, because of its retrospective design and because the patients’ records and information were anonymized and de-identified before analysis.

Shock wave lithotripsy
SWL was performed using an electro-conductive lithotripter (EDAP Sonolith Praktis, Technomed, Lyon, France) until December 2011. On January 2012, this lithotripter was replaced by an electromagnetic generative lithotripter (Dornier Compact Delta II lithotripter, Dornier Medtech, Wessling, Germany). All SWL procedures were performed under fluoroscopic guidance. The total numbers of shocks ranged from 2500 to 4000 in each session, at a rate of 60–90 shock waves per minute and at a launch intensity ranging from 16 to 55 MPa.

Demographic data and non-contrast computed tomography stone characteristics
A detailed medical history that included the number of past stone events was obtained for each patient. Stone characteristics, such as location, maximal stone length (MSL), stone heterogeneity index (SHI), skin-to-stone distance (SSD), and mean stone density (MSD), were evaluated. SSD was measured in the axial plane, 45° from the vertical axis.6 MSL was the longest stone length measured in three dimensions on non-contrast computed tomography (NCCT) images. We used the GE Centricity system (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) for the measuring procedures. MSD was measured using bone windows on the magnified axial NCCT image of the stone in the maximal diameter; the elliptical region of interest incorporated the largest cross-sectional area of the stone without including adjacent soft tissue.10 The SHI was defined as the standard deviation of Hounsfield units (HU) in the same way used by Lee, et al.11 Successful SWL treatment of the ureteral stone was defined as for patients who were rendered stone-free or had asymptomatic residual fragments ≤3 mm in largest stone diameter on simple X-ray at 2 weeks after a single SWL treatment and who did not require additional treatment within the 3-month follow-up period.12

Hydronephrosis grading system
Hydronephrosis was graded according to the degrees of change in the upper collecting system and defined using the Society of Fetal Ultrasound Grade system.13 Grade 0 hydronephrosis was defined as no dilatation of the renal pelvis, with calyceal walls opposed to each other. Grade 1 was defined as dilatation of the renal pelvis without dilatation of the calyces (could also be present in the extra renal pelvis), and no parenchymal atrophy. Grade 2 hydronephrosis was defined as dilatation of the renal pelvis (mild) and calyces (the pelvicalyceal pattern was retained), and no parenchymal atrophy. Grade 3 was defined as moderate dilatation of the renal pelvis and calyces, blunting of the fornices and flattening of the papillae, and possible mild cortical thinning. Grade 4 hydronephrosis was defined as gross dilatation of the renal pelvis and calyces with a ballooned appearance, loss of the borders between the renal pelvis, calyces, and renal atrophy indicated by the presence of cortical thinning.

Statistical analyses
The statistical comparisons of the continuous variables from the patients’ demographic information were performed using Student’s or Welch’s two-sample t-tests or the Wilcoxon rank sum test. One-way analysis of variance was used for subgroup analysis. Categorical variables were compared using Pearson’s chi-square tests. Univariate and binomial multivariate logistic regression analyses were performed to identify factors that predicted post-SWL outcomes. To exclude potential multicollinearity between variables, variance inflation factors for these variables were also analyzed. The statistical analyses were performed using R software (version 3.0.3, R Foundation for Statistical Computing, Vienna, Austria; http://www.r-project.org) and SPSS 23 software (IBM Co., Armonk, NY, USA).

RESULTS
Table 1 presents the results for the baseline characteristics of the 700 patients who underwent an initial SWL treatment for single
ureteral calculus. The mean patient age for the cohort was 52.5±13.8 years. The mean MSL and SSD values were 9.2±3.9 and 110.8±18.9 mm, respectively. The mean MSD and SHI values were 707.0±272.1 and 244.9±110.1 HU, respectively. The results for pretreatment hydronephrosis grade in patients with ureteral stone were 76 (10.9%) cases of grade 0, 383 (46.9%) cases of grade 1, 177 (25.3%) cases of grade 2, 100 (14.3%) cases of grade 3, and 19 (2.7%) cases of grade 4 hydronephrosis. There were 573 (81.9%) cases of upper ureteral stone, 48 (6.9%) cases of mid-ureteral stone, and 79 (11.3%) cases of lower ureteral stone. The overall one-session success rate was 69.6%. The data from the study population were divided into two groups (treatment success or failure). The results indicated that there were statistical differences between the two groups in age (51.8±13.8 years in success group vs. 54.1±13.8 years in failure group; p=0.042), MSL (8.3±3.2 vs. 11.2±4.5, respectively; p<0.001), MSD (642.6±243.8 vs. 854.3±276.4, respectively; p<0.001), SHI (252.0±114.0 vs. 228.5±98.9, respectively; p=0.006), and grade of hydronephrosis (p<0.001). The one-session success rates were 68.4, 75.0, 75.1, 54.0, and 10.5% for patients with hydronephrosis grades 0, 1, 2, 3, and 4, respectively (Table 2). The results indicated a statistically significant association between hydronephrosis grade and one-session success rate and stone location were also significantly different (p<0.001). Among three groups with hydronephrosis grade 0–1, grade 2, and grades 3–4, there were statistically significant differences in sex (p<0.001), MSL (p<0.001), MSD (p<0.001), stone location (p<0.022), and one-session success rate (p<0.001) (Table 3). The univariate logistic regression models revealed that the following predictive factors were associated with SWL outcome after ureteral stone treatment: age [odds ratio (OR): 0.988, 95% confidence intervals (CI): 0.976–0.999; p=0.043], MSL (OR: 0.822, 95% CI: 0.782–0.861; p<0.001), MSD (OR: 0.997, 95% CI: 0.996–0.998; p<0.001), higher SHI (OR: 1.002, 95% CI: 1.001–1.004; p=0.010), and hydronephrosis grade (OR: 0.309, 95% CI: 0.206–0.463; p<0.001). Multivariate analyses revealed that shorter MSL, lower MSD, and higher SHI were independent predictors and that hydronephrosis grades 3 and 4 were negative predictors of one-session success after SWL treatment for ureteral stone (Table 4).

**DISCUSSION**

SWL has been established as the preferred treatment for urinary stones due to its noninvasiveness, few absolute contraindications, and favorable clinical outcomes. However, if a satisfactory outcome for SWL is not expected for a specific clinical situation, then the other benefits (e.g., non-invasiveness) are no longer available to the patient. Therefore, it is essential to accurately predict individual treatment outcomes in terms of proper treatment selection for patients who are candidates for SWL. Previous studies of SWL success rates have revealed that age, sex, and stone characteristics (stone site, size, and density) are factors associated with post-treatment stone-free rates. Numerical values for MSL, MSD, and SHI were 707.0±272.1 and 244.9±110.1 HU, respectively. The mean MSD and SHI values were 75.0±13.8 years. The mean MSL and SSD values were 9.2±3.9 and 110.8±18.9 mm, respectively. The mean MSD and SHI values were 707.0±272.1 and 244.9±110.1 HU, respectively. The results indicated a statistically significant association between hydronephrosis grade and one-session success rate and stone location were also significantly different (p<0.001). Among three groups with hydronephrosis grade 0–1, grade 2, and grades 3–4, there were statistically significant differences in sex (p<0.001), MSL (p<0.001), MSD (p<0.001), stone location (p<0.022), and one-session success rate (p<0.001) (Table 3). The univariate logistic regression models revealed that the following predictive factors were associated with SWL outcome after ureteral stone treatment: age [odds ratio (OR): 0.988, 95% confidence intervals (CI): 0.976–0.999; p=0.043], MSL (OR: 0.822, 95% CI: 0.782–0.861; p<0.001), MSD (OR: 0.997, 95% CI: 0.996–0.998; p<0.001), higher SHI (OR: 1.002, 95% CI: 1.001–1.004; p=0.010), and hydronephrosis grade (OR: 0.309, 95% CI: 0.206–0.463; p<0.001). Multivariate analyses revealed that shorter MSL, lower MSD, and higher SHI were independent predictors and that hydronephrosis grades 3 and 4 were negative predictors of one-session success after SWL treatment for ureteral stone (Table 4).

**Table 1. Comparison of Clinical Characteristics between One-Session Success and Failure after Shock Wave Lithotripsy for Ureteral Stone**

| Comparison of Clinical Characteristics between One-Session Success and Failure after Shock Wave Lithotripsy for Ureteral Stone | Total cohort | Success group | Failure group | p value |
|---|---|---|---|---|
| Patients, n | 700 | 487 | 213 | 0.042* |
| Mean age±SD (yr) | 52.5±13.8 | 51.8±13.8 | 54.1±13.8 | 0.042* |
| Sex, n (%) | | | | 0.206† |
| Male | 454 (64.9) | 308 (63.2) | 146 (68.5) | |
| Female | 246 (35.1) | 179 (36.8) | 67 (31.5) | |
| Mean MSL±SD (mm) | 9.2±3.9 | 8.3±3.2 | 11.2±4.5 | <0.001* |
| Mean SSD±SD (mm) | 110.8±18.9 | 110.6±18.9 | 11.1±19.2 | 0.751* |
| Mean MSD±SD (HU) | 707.0±272.1 | 642.6±243.8 | 854.3±276.4 | <0.001* |
| Mean SHI±SD (HU) | 244.9±110.1 | 252.0±114.0 | 228.5±98.9 | 0.006* |
| Hydronephrosis grade, n (%) | | | | <0.001† |
| Grade 0 | 76 (10.9) | 52 (10.7) | 24 (11.3) | |
| Grade 1 | 328 (46.9) | 246 (50.5) | 82 (38.5) | |
| Grade 2 | 177 (25.3) | 133 (27.3) | 44 (20.7) | |
| Grade 3 | 100 (14.3) | 54 (11.1) | 46 (21.6) | |
| Grade 4 | 19 (2.7) | 2 (0.4) | 17 (8.0) | |
| Stone location, n (%) | | | | 0.510† |
| Upper | 573 (81.9) | 403 (82.7) | 170 (79.8) | |
| Middle | 48 (6.9) | 30 (6.2) | 18 (8.5) | |
| Lower | 79 (11.3) | 54 (11.1) | 25 (11.7) | |
| One-session success, n (%) | 487 (69.6) | 487 (69.6) | 0 (0) | |

HU, Hounsfield units; MSL, mean stone density; MSD, maximal stone length; SD, standard deviation; SHI, stone heterogeneity index; SSD, skin-to-stone distance.

*Based on Student’s or Welch’s two-sample t-test, †Based on Pearson’s chi-square test with Yates’ continuity correction.
Table 2. Comparison of Clinical Characteristics among Groups According to Hydronephrosis Grade

|                        | Grade 0 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | p value |
|------------------------|---------|---------|---------|---------|---------|---------|
| Patients, n            | 76      | 383     | 177     | 100     | 19      |         |
| Mean age±SD, (yr)      | 51.1±14.5 | 51.8±13.8 | 53.5±13.5 | 54.1±14.2 | 52.5±13.4 | 0.434*  |
| Sex, n (%)             |         |         |         |         |         | 0.029†  |
| Male                   | 55 (72.4) | 223 (68.0) | 112 (63.3) | 52 (52.0) | 12 (63.2) |         |
| Female                 | 21 (27.6) | 105 (32.0) | 65 (36.7) | 48 (48.0) | 7 (36.8) |         |
| Mean MSL±SD (mm)       | 7±2.8 | 8±3.5 | 9.2±3.5 | 11.7±4.8 | 13±3.3 | <0.001* |
| Mean SSD±SD (mm)       | 106.8±19.7 | 110.8±18.5 | 111.5±18.2 | 111.0±20.6 | 116.8±19.3 | 0.239*  |
| Mean MSD±SD (HU)       | 694.0±235.4 | 687.7±283.2 | 656.2±216.5 | 809.5±287.5 | 1026.5±273.8 | <0.001* |
| Mean SHI±SD (HU)       | 237.1±80.4 | 238.5±112.6 | 250.3±108.1 | 253.7±121.0 | 287.8±122.0 | 0.247*  |
| Stone location, n (%)  |         |         |         |         |         | <0.001† |
| Upper                  | 56 (73.7) | 283 (86.3) | 145 (81.9) | 73 (73.0) | 16 (84.2) |         |
| Middle                 | 5 (6.6) | 9 (2.7) | 16 (9.0) | 15 (15.0) | 3 (15.8) |         |
| Lower                  | 15 (19.7) | 36 (11.0) | 16 (9.0) | 12 (12.0) | 0 (0.0) |         |
| One-session success, n (%) | 52 (68.4) | 246 (75.0) | 133 (75.1) | 54 (54.0) | 2 (10.5) | <0.001† |

HU, Hounsfield units; MSD, mean stone density; MSL, maximal stone length; SD, standard deviation; SHI, stone heterogeneity index; SSD, skin-to-stone distance.

*Based on Student’s or Welch’s two-sample t-test, †Based on Pearson’s chi-square test with Yates’ continuity correction.

Table 3. Comparison of Clinical Characteristics among Groups with Pretreatment Hydronephrosis Grades 0–1, Grade 2, and Grades 3–4

|                        | Total cohort | Grades 0–1 | Grade 2 | Grades 3–4 | p value |
|------------------------|--------------|------------|---------|------------|---------|
| Patients, n            | 700          | 581        | 177     | 119        |         |
| Mean age±SD, (yr)      | 52.5±13.8    | 52.2±13.8  | 53.5±13.5 | 53.8±14.0 | 0.182*  |
| Sex, n (%)             |              |            |         |            | <0.001† |
| Male                   | 454 (64.9)   | 390 (67.1) | 112 (63.3) | 64 (53.8) |         |
| Female                 | 246 (35.1)   | 191 (32.9) | 65 (36.7) | 55 (46.2) |         |
| Mean MSL±SD (mm)       | 9.2±3.9      | 8.6±3.4    | 9.3±3.5 | 12.0±4.6 | <0.001* |
| Mean SSD±SD (mm)       | 110.8±18.9   | 110.5±18.6 | 111.5±18.3 | 112.0±20.4 | 0.535*  |
| Mean MSD±SD (HU)       | 707.0±272.1  | 678.9±258.5 | 656.2±216.5 | 844.2±295.2 | <0.001* |
| Mean SHI±SD (HU)       | 244.9±110.1  | 241.9±107.6 | 250.4±108.2 | 259.1±121.3 | 0.144*  |
| Stone location, n (%)  |              |            |         |            | <0.022† |
| Upper                  | 573 (81.9)   | 484 (83.3) | 145 (81.9) | 89 (74.8) |         |
| Middle                 | 48 (6.9)     | 30 (5.2)   | 16 (9.0) | 18 (15.1) |         |
| Lower                  | 79 (11.3)    | 67 (11.5)  | 16 (9.0) | 12 (10.1) |         |
| One-session success, n (%) | 487          | 431 (74.2) | 133 (75.1) | 56 (47.1) | <0.001† |

HU, Hounsfield units; MSD, mean stone density; MSL, maximal stone length; SD, standard deviation; SHI, stone heterogeneity index; SSD, skin-to-stone distance.

*Based on Student’s or Welch’s two-sample t-test, †Based on Pearson’s chi-square test with Yates’ continuity correction.

of stones, a history of urolithiasis, the presence of renal colic, the degree of hydronephrosis, and use of a ureteral stent are other factors that affect success rate. MSL is a potentially useful independent predictor of SWL outcome. Patients with larger stones are more likely to experience failure of treatment and require further intervention. MSD is also an independent factor associated with SWL outcome. MSD is the mean value of the HU of each pixel in a specific stone area and can be easily determined from NCCT images using a picture archiving and communication system. SSD has been extensively investigated as a predictor of SWL success, but its use remains controversial for patients with ureter stones: SSD has been deemed a significant factor in one-half of all published studies. Recently, SHI was introduced as a novel independent predictor of SWL success in patients with ureteral stone and as a useful clinical parameter for stone fragility. Other studies of stone sites have found that treatment of proximal and distal ureteral stones results in better outcomes, compared with treatment of mid-ureteral stones. However, the results of recent studies suggest that there are no differences between groups in regards to stone site and treatment results. A history of urolithiasis has been reported as a negative factor affecting SWL success. Ureteral stenting is a significant factor affecting stone-free rates. Our study revealed that MSL, MSD, SHI, and severe hydronephrosis were significant predictors of one-session success rate after SWL treatment of single ureteral stone. Several studies have evaluated the effects of preoperative hydronephrosis on the success rate of SWL; their findings have been inconsistent.
Hydronephrosis and Ureteral Stone

Table 4. Univariate and Multivariate Logistic Regression Analysis of Various Clinical Parameters for the Prediction of One-Session Success after Shock Wave Lithotripsy

| Parameter                  | Odds ratio | 95% confidence intervals         | p value |
|----------------------------|------------|----------------------------------|---------|
| Univariate analysis        |            |                                  |         |
| Age                        | 0.988      | 0.976–0.999                      | 0.043   |
| Sex (male)                 | 0.789      | 0.558–1.110                      | 0.177   |
| MSL                        | 0.822      | 0.782–0.861                      | <0.001  |
| MSD                        | 0.997      | 0.996–0.998                      | <0.001  |
| SSD                        | 0.999      | 0.990–1.007                      | 0.750   |
| SHI                        | 1.002      | 1.001–1.004                      | 0.010   |
| Stone location             |            |                                  |         |
| Upper                      |            |                                  |         |
| Lower                      |            |                                  |         |
| Hydronephrosis Grade 3 & 4 |            |                                  |         |
| Multivariate analysis      |            |                                  |         |
| Age                        | 0.992      | 0.979–1.006                      | 0.267   |
| MSL                        | 0.888      | 0.841–0.934                      | <0.001  |
| MSD                        | 0.996      | 0.995–0.997                      | <0.001  |
| SHI                        | 1.007      | 1.005–1.010                      | <0.001  |
| Hydronephrosis Grade 3 & 4 | 0.601      | 0.368–0.988                      | 0.043   |

MSD, mean stone density; MSL, maximal stone length; SHI, stone heterogeneity index; SSD, skin-to-stone distance.

ing to the absence or presence of hydronephrosis. There were no significant differences between the degree of stone-induced hydronephrosis and SWL outcome (83.2% in the non-hydronephrotic group vs. 74.2% in hydronephrotic group; p=0.27). They performed a similar study of 284 patients with proximal ureteral stone and found that the stone-free rate was 80.3% in the hydronephrotic group, compared with 89.1% in the patients without hydronephrosis (p=0.12). The results of Wang, et al.'s multivariate analysis also suggested that hydronephrosis was not a significant factor for SWL treatment success rate (OR: 1.272, 95% CI: 0.471–3.433; p=0.635). In contrast, Kageyama, et al. found that mid to lower ureteral stone and moderate-to-severe hydronephrosis were negative predictive factors of SWL treatment success rate. Delakas, et al. also found that the likelihood of SWL treatment failure increases as the severity of the obstruction increases; hydronephrosis was associated with poorer results after SWL treatment (borderline significance; OR: 1.93, 95% CI: 0.99–3.77; p=0.063). The results of our multivariate analyses indicated that severe hydronephrosis (grades 3 and 4) is an independent predictor of a poor outcome after SWL treatment for ureteral stone (Table 4).

Generally, ureteral stones cause sudden ureteral obstruction that results in the development of hydronephrosis; continuous obstruction results in deterioration of renal function. Hydronephrosis has adverse effects on renal function and decreases ureteral peristalsis and hydraulic pressure. These changes may adversely affect the expulsion of ureteral stones. This relationship may help explain our results. Severe hydronephrosis can also be linked to ureteral stone impaction into the ureteral mucosa. Impacted stones are frequently associated with ureteral polyps or strictures. A chronically impacted stone may cause inflammation and edema of the ureteral wall; these changes may also involve the surrounding tissues. The impacted stone can thus cause a more complete ureteral obstruction that results in severe hydronephrosis. Impacted ureteral stones are more difficult to fragment using SWL, because of the lack of a natural expansion space for the targeted stones. There are currently two clinical definitions used for impacted stones. The first commonly used definition of impaction is the inability to pass a wire or catheter beyond the stone at the initial attempt. The second definition of impaction is that the stone has remained at the same location in the ureter for more than 2 months.

Most urologists know that impacted stones are much more resistant to treatment using SWL. However, if currently available definitions for stone impaction are used, it is almost impossible to determine whether a specific ureteral stone is impacted at initial diagnosis. For these reasons, severe hydronephrosis can be used as ancillary clinical evidence of ureteral stone impaction in patients with ureteral stone when SWL is being considered as a primary treatment. European Association of Urology (EAU) guidelines recommend laparoscopic ureterolithotomy for treatment of large impacted stones when endoscopic lithotripsy or SWL has failed. However, our study revealed one-session success rates of 54.0% and 10.5% in patients with hydronephrosis grades 3 and 4, respectively (Table 2). Therefore, even though SWL is less invasive, compared with surgical lithotripsy; we are not sure whether physicians should offer SWL as a first-line therapy for ureteral stone patients with concomitant grade 4 hydronephrosis. Physicians and patients should discuss this low SWL performance rate before selec-
tion of SWL as a treatment for ureteral stones with accompanying grade 4 hydronephrosis.

This study had some inherent limitations, because the use of a retrospective study design may have introduced sampling bias. However, we used a relatively large cohort of patients who underwent SWL for treatment of single ureteral stone. The presence of renal stones and anatomical considerations, including the location of calyx and renal pelvic stones or stones in the infundibulopelvic angle, were additional possible sources of bias. To overcome this type of limitation and more clearly elucidate the effects of various stone-related factors on SWL outcomes, we limited the study population to patients who only had ureteral stones. Unlike previous studies, we also classified hydronephrosis grade into five groups using a current grading system. This approach resulted in a better characterization of the contribution of hydronephrosis to treatment outcome. Prospective studies that use large sample sizes are needed to confirm our results regarding the relationships between pretreatment hydronephrosis and stone clearance.

In conclusion, the presence of grade 3 or 4 hydronephrosis before SWL was a negative predictive factor for one-session success in patients treated for a single ureteral stone. Severe hydronephrosis can be used as an indicator of possible ureteral stone impaction. In the presence of severe hydronephrosis, especially grade 4 hydronephrosis, physicians should be cautious when choosing and offering SWL as the primary treatment for ureteral stone.

ACKNOWLEDGEMENTS

This study was supported by a faculty research grant from the Yonsei University College of Medicine for 2014 (6-2014-0156).

REFERENCES

1. Frabboni R, Santi V, Ronchi M, Gaiani S, Costanza N, Ferrari G, et al. In situ echoguided extracorporeal shock wave lithotripsy of ureteric stones with the Dornier MPL 9000: a multicentric study group. Br J Urol 1994;73:487-93.
2. Creagh TA, Williams NN, Cronin K, Kerin MJ, Smith JM, Fitzpatrick JM. In situ ESWL for ureteric calculi: the optimum treatment? Br J Urol 1993;72:348-50.
3. Singal RK, Denstedt JD. Contemporary management of ureteral stones. Urol Clin North Am 1997;24:59-70.
4. Srivastava A, Ahlawat R, Kumar A, Kapoor R, Bhandari M. Management of impacted upper ureteric calculi: results of lithotripsy and percutaneous litholapaxy. Br J Urol 1992;70:252-7.
5. Delakas D, Karyotis I, Daskalopoulos G, Lianos E, Mavromanolakis E. Independent predictors of failure of shockwave lithotripsy for ureteral stones employing a second-generation lithotripter. J Endourol 2003;17:201-5.
6. Wang M, Shi Q, Wang X, Yang K, Yang R. Prediction of outcome of extracorporeal shock wave lithotripsy in the management of ureteric calculi. Urol Res 2011;39:51-7.
7. El-Assmy A, El-Nahas AR, Youssif RF, El-Hefnawy AS, Sheikh KZ. Impact of the degree of hydronephrosis on the efficacy of in situ extracorporeal shock-wave lithotripsy for proximal ureteral calculi. Scand J Urol Nephrol 2007;41:208-13.
8. Kageyama S, Hirai S, Higashi Y. [An investigation of factors associated with failure of extracorporeal shock wave lithotripsy for ureteral calculi]. Hinyokika Kiyo 2006;46:371-6.
9. Cho KS, Jung HD, Ham WS, Chung DY, Kang YJ, Jung WS, et al. Optimal skin-to-stone distance is a positive predictor for successful outcomes in upper ureter calculi following extracorporeal shock wave lithotripsy: a Bayesian model averaging approach. PLoS One 2015;10:e0144912.
10. Chung DY, Cho KS, Lee DH, Han JH, Kang DH, Jung HD, et al. Impact of colic pain as a significant factor for predicting the stone free rate of one-session shock wave lithotripsy for treating ureter stones: a Bayesian logistic regression model analysis. PLoS One 2015;10:e0123800.
11. Lee JY, Kim JH, Kang DH, Chung DY, Lee DH, Jung HD, et al. Stone heterogeneity index as the standard deviation of Hounsfield units: a novel predictor for shock-wave lithotripsy outcomes in ureter calculi. Sci Rep 2016;6:23988.
12. Seitz C, Fajkovic H, Waldert M, Tanovic E, Remzi M, Kramer G, et al. Extracorporeal shock wave lithotripsy in the treatment of proximal ureteral stones: does the presence and degree of hydronephrosis affect success? Eur Urol 2006;49:378-83.
13. Fernbach SK, Maizels M, Conway JJ. Ultrasound grading of hydronephrosis: introduction to the system used by the Society for Fetal Urology. Pediatr Radiol 1993;23:478-80.
14. Skolarikos A, Alivizatos G, de la Rosette J. Extracorporeal shock wave lithotripsy 25 years later: complications and their prevention. Eur Urol 2006;50:981-90.
15. Augustin H. Prediction of stone-free rate after ESWL. Eur Urol 2007;52:318-20.
16. Kim HH, Lee JH, Park MS, Lee SE, Kim SW. In situ extracorporeal shockwave lithotripsy for ureteral calculi: investigation of factors influencing stone fragmentation and appropriate number of sessions for changing treatment modality. J Endourol 1996;10:501-5.
17. Gupta NP, Ansari MS, Kesavani P, Kapoor A, Mukhopadhyay S. Role of computed tomography with no contrast medium enhancement in predicting the outcome of extracorporeal shock wave lithotripsy for urinary calculi. BJU Int 2005;95:1285-8.
18. Lim KH, Jung JH, Kwon JH, Lee YS, Bae J, Cho MC, et al. Can stone density on plain radiography predict the outcome of extracorporeal shockwave lithotripsy for ureteral stones? Korean J Urol 2015;56:56-62.
19. Hofbauer J, Tuerck C, Hoabarth K, Hasun R, Marberger M. ESWL in situ or ureteroscopy for ureteric stones? World J Urol 1993;11:54-8.
20. Kanoa K, Nakashima J, Nakagawa K, Asakura H, Miyajima A, Oya M, et al. Preoperative nomograms for predicting stone-free rate after extracorporeal shock wave lithotripsy. J Urol 2006;176(4 Pt 1):1453-6.
21. Abe T, Akakura K, Kawaguchi M, Ueda T, Ichikawa T, Itô H, et al. Outcomes of shockwave lithotripsy for upper urinary-tract stones: a large-scale study at a single institution. J Endourol 2005;19:768-73.
22. Muğiya S, Ito T, Maruyama S, Hadano S, Nagae H. Endoscopic features of impacted ureteral stones. J Urol 2004;171:89-91.
23. Morgentaler A, Bridge SS, Dretler SP. Management of the impacted ureteral calculi. J Urol 1990;143:263-6.
24. Muğiya S, Nagata M, Uno-No T, Takayama T, Suzuki K, Fujita K. Endoscopic management of impacted ureteral stones using a small caliber ureteroscope and a laser lithotriptor. J Urol 2000;164:329-31.
25. Türk C, Petrić A, Sarica K, Seitz C, Skolarikos A, Straub M, et al. EAU guidelines on interventional treatment for urolithiasis. Eur Urol 2016;69:475-82.

https://doi.org/10.3349/ymj.2017.58.5.1000

1005